| Start: | Sep 24, 2024 - 5:00 pm |
| End: | Sep 24, 2024 - 6:15 pm |
| Venue: | Webinar (Zoom event) |
| Event website: | https://events.zoom.us/ev/AqqRJKuEiyr_P7ObdeZdR3sB55mUXey_-qqYloWdtJwXhc5539YC~Ag9O43pnhneo1YAgIQSnVdGkXajfYXvud7CEyW1NU6ZYjBo_4jjtsjW8GA?lmt=1725532466000 |
Join us for an exclusive webinar hosted by the European Technology Platform on Nanomedicine (ETPN) and co-organized with NanoVation Therapeutics, where leading experts will discuss the latest advancements in lipid nanoparticle (LNP) technologies. This event will delve into cutting-edge innovations aimed at enabling the delivery of nucleic acids beyond the liver, opening new therapeutic avenues for a range of diseases. REGISTER HERE!
Agenda:
- 5:00 – 5:05 PM CET: Welcome and Introduction
by Prof. Raymond Schiffelers, Chairman of ETPN.
- 5:05 – 5:25 PM CET: Historical Perspective on LNP Development
by Dr. Pieter Cullis, Professor & Entrepreneur, University of British Columbia (UBC). Dr. Cullis will explore the evolution of LNP technologies and their transformative impact on modern medicine.
- 5:25 – 5:45 PM CET: Next Generation LNPs
by Dr. Dominik Witzigmann, CEO of NanoVation Therapeutics. Dr. Witzigmann will present the latest innovations in LNP technologies, focusing on their application for extrahepatic delivery of nucleic acids.
- 5:45 – 6:00 PM CET: T Cell Applications
by Dr. Laura Evgin, Assistant Professor, University of British Columbia (UBC). Dr. Evgin will discuss the emerging role of LNPs in targeting T cells for immunotherapy.
- 6:00 – 6:15 PM CET: Q&A Session moderated
by Dr. Alexandre Ceccaldi, General Secretary of ETPN. This interactive session will provide an opportunity for participants to engage directly with the speakers and ask in-depth questions.
Why You Should Attend:
This webinar is a unique opportunity to gain insights from pioneers in the field of lipid nanoparticle (LNP) technology and extrahepatic nucleic acid delivery. Whether you are a researcher, biotech professional, or academic, this event will provide valuable knowledge on the latest advancements that are shaping the future of genetic medicines.
Additionally, as NanoVation Therapeutics is one of the newest members of the ETPN, this webinar marks the beginning of a concerted effort to build a vibrant community focused on nano-enabled gene and cell therapy in Europe. Don’t miss the chance to be part of this movement and connect with like-minded professionals from around the globe!
About NanoVation Therapeutics™ (NTx):
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery).
NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.
NanoVation partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases. For additional information, please visit nanovationtx.com or follow NanoVation Therapeutics on LinkedIn.
About ETPN:
The European Technology Platform on Nanomedicine (ETPN) is a dynamic community fostering research, development, and clinical integration of cutting-edge nanotechnology innovations in healthcare. As Europe’s leading nanomedicine think tank, ETPN collaborates with over 120 entities to support funding in Nanomedicine, propel technological advancements and streamline clinical applications, ensuring that tomorrow’s solutions reach patients efficiently. Learn more about ETPN: https://www.etp-nanomedicine.eu
